Cholesterol metabolism and resistance to tamoxifen

Current Opinion in Pharmacology

Volumn 12, Issue 6, 2012, Pages 683-689

  Poirot, Marc ^a,b   Silvente Poirot, Sandrine ^a,b   Weichselbaum, Ralph R ^c  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 (2 DIMETHYLAMINOETHOXY)PHENYL]ESTRADIOL; AFIMOXIFENE; ALPHA TOCOPHEROL; CHOLESTEROL 5,6 EPOXIDE HYDROLASE; CHOLESTEROL ACYLTRANSFERASE; CLOMIFENE; DOXORUBICIN; HYDROLASE; MUCIN 1; N PYRROLIDINO 2 [4 (BENZYL)PHENOXYETHANAMINE]; RALOXIFENE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TESMILIFENE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CELL DEATH; CELL DIFFERENTIATION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DRUG BINDING; DRUG MECHANISM; DRUG RESISTANCE; ENZYME INHIBITION; FATTY ACID METABOLISM; GENETIC TRANSCRIPTION; HUMAN; MICROSOMAL ANTIESTROGEN BINDING SITE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84870566249     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.09.007     Document Type: Review

References (44)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics CA Cancer J Clin 59 2009 225 249
2. V.C. Jordan Chemoprevention of breast cancer with selective oestrogen-receptor modulators Nat Rev Cancer 7 2007 46 53
3. M. Poirot Four decades of discovery in breast cancer research and treatment - an interview with V. Craig Jordan Int J Dev Biol 55 2011 703 712
4. A. Goldhirsch, W.C. Wood, A.S. Coates, R.D. Gelber, B. Thurlimann, and H.J. Senn Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 2011 1736 1747
5. R. Clarke, M.C. Liu, K.B. Bouker, Z. Gu, R.Y. Lee, Y. Zhu, T.C. Skaar, B. Gomez, K. O'Brien, and Y. Wang Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 2003 7316 7339
6. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat Rev Cancer 9 2009 874 885
7. D.W. Kufe MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches Oncogene 2012
8. S.P. Pitroda, N.N. Khodarev, M.A. Beckett, D.W. Kufe, and R.R. Weichselbaum MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment Proc Natl Acad Sci USA 106 2009 5837 5841
9. Y. Zhou, H. Rajabi, and D. Kufe Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors Mol Pharmacol 79 2011 886 893
10. B.G. Bitler, I. Menzl, C.L. Huerta, B. Sands, W. Knowlton, A. Chang, and J.A. Schroeder Intracellular MUC1 peptides inhibit cancer progression Clin Cancer Res 15 2009 100 109
11. P. de Medina, G. Favre, and Poirot M Multiple targeting by the antitumor drug tamoxifen: a structure-activity study Curr Med Chem Anticancer Agents 4 2004 491 508
12. P. de Medina, B.L. Payre, J. Bernad, I. Bosser, B. Pipy, S. Silvente-Poirot, G. Favre, J.C. Faye, and M. Poirot Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells J Pharmacol Exp Ther 308 2004 1165 1173
13. M.R. Tosi, and V. Tugnoli Cholesteryl esters in malignancy Clin Chim Acta 359 2005 27 45
14. P. de Medina, S. Genovese, M. Paillasse, M. Mazaheri, S. Subra-Caze, K. Bystricky, M. Curini, S. Silvente-Poirot, F. Epifano, and Poirot M Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors Mol Pharmacol 78 2010 827 836
15. S. Bemlih, M.D. Poirier, and M.D. El Andaloussi Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines Cancer Biol Ther 9 2010 1025 1032
16. C.J. Antalis, T. Arnold, T. Rasool, B. Lee, K.K. Buhman, and R.A. Siddiqui High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation Breast Cancer Res Treat 122 2010 661 670
17. M.R. Paillasse, P. de Medina, G. Amouroux, L. Mhamdi, M. Poirot, and S. Silvente-Poirot Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion J Lipid Res 50 2009 2203 2211
18. C.J. Antalis, A. Uchida, K.K. Buhman, and R.A. Siddiqui Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification Clin Exp Metastasis 28 2011 733 741
19. P. de Medina, N. Boubekeur, P. Balaguer, G. Favre, S. Silvente-Poirot, and M. Poirot The prototypical inhibitor of cholesterol esterification Sah 58-035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors J Pharmacol Exp Ther 319 2006 139 149
20. H. Gylling, S. Pyrhonen, E. Mantyla, H. Maenpaa, L. Kangas, and T.A. Miettinen Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer J Clin Oncol 13 1995 2900 2905
21. B. Kedjouar, P. de Medina, M. Oulad-Abdelghani, B. Payre, S. Silvente-Poirot, G. Favre, J.C. Faye, and Poirot M Molecular characterization of the microsomal tamoxifen binding site J Biol Chem 279 2004 34048 34061
22. P. de Medina, M.R. Paillasse, G. Segala, F. Khallouki, S. Brillouet, F. Dalenc, F. Courbon, M. Record, M. Poirot, and S. Silvente-Poirot Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands Chem Phys Lipids 164 2011 432 437
23. P. de Medina, M.R. Paillasse, G. Segala, M. Poirot, and S. Silvente-Poirot Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands Proc Natl Acad Sci USA 107 2010 13520 13525
24. P. de Medina, B. Payre, N. Boubekeur, J. Bertrand-Michel, F. Terce, S. Silvente-Poirot, and M. Poirot Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism Cell Death Differ 16 2009 1372 1384
25. D.J. Klionsky, F.C. Abdalla, H. Abeliovich, R.T. Abraham, A. Acevedo-Arozena, K. Adeli, L. Agholme, M. Agnello, P. Agostinis, and J.A. Aguirre-Ghiso Guidelines for the use and interpretation of assays for monitoring autophagy Autophagy 8 2012 445 544
26. P.V. Schoenlein, S. Periyasamy-Thandavan, J.S. Samaddar, W.H. Jackson, and J.T. Barrett Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance Autophagy 5 2009 400 403
27. G. Segala, P. de Medina, M.R. Paillasse, V.C. Jordan, S. Silvente-Poirot, and M. Poirot Abstract 956: The liver-X-receptor-α is involved in the induction by Tamoxifen of breast cancer cell differentiation and death Cancer Res 72 2012 956 Abstract nr
28. B. Payre, P. de Medina, N. Boubekeur, L. Mhamdi, J. Bertrand-Michel, F. Terce, I. Fourquaux, D. Goudouneche, M. Record, and M. Poirot Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism Mol Cancer Ther 7 2008 3707 3718
29. L. Yin, Z. Wu, D. Avigan, J. Rosenblatt, R. Stone, S. Kharbanda, and D. Kufe MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells Blood 117 2011 4863 4870
30. K. Kuehnle, A. Crameri, R.E. Kalin, P. Luciani, S. Benvenuti, A. Peri, F. Ratti, M. Rodolfo, L. Kulic, and F.L. Heppner Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress Mol Cell Biol 28 2008 539 550
31. C. Wu, I. Miloslavskaya, S. Demontis, R. Maestro, and K. Galaktionov Regulation of cellular response to oncogenic and oxidative stress by Seladin-1 Nature 432 2004 640 645
32. Poirot M, Silvente-Poirot S: Cholesterol-5,6-epoxides: Chemistry, biochemistry, metabolic fate and cancer. Biochimie 2012, in press, http://dx.doi.org/10.1016/j.biochi.2012.05.006.
33. S. Silvente-Poirot, and M. Poirot Cholesterol epoxide hydrolase and cancer Curr Opin Pharmacol 12 2012 696 703
34. R. Schiff, P. Reddy, M. Ahotupa, E. Coronado-Heinsohn, M. Grim, S.G. Hilsenbeck, R. Lawrence, S. Deneke, R. Herrera, and G.C. Chamness Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo J Natl Cancer Inst 92 2000 1926 1934
35. P. Luciani, C. Deledda, F. Rosati, S. Benvenuti, I. Cellai, F. Dichiara, M. Morello, G.B. Vannelli, G. Danza, and M. Serio Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures Endocrinology 149 2008 4256 4266
36. Y. Wang, P.M. Rogers, K.R. Stayrook, C. Su, G. Varga, Q. Shen, S. Nagpal, and T.P. Burris The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene Mol Pharmacol 74 2008 1716 1721
37. K. Engelmann, H. Shen, and O.J. Finn MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1 Cancer Res 68 2008 2419 2426
38. S. Fatrai, H. Schepers, H. Tadema, E. Vellenga, S.M. Daenen, and J.J. Schuringa Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases Exp Hematol 36 2008 1254 1265
39. N. Misaghian, G. Ligresti, L.S. Steelman, F.E. Bertrand, J. Basecke, M. Libra, F. Nicoletti, F. Stivala, M. Milella, and A. Tafuri Targeting the leukemic stem cell: the Holy Grail of leukemia therapy Leukemia 23 2009 25 42
40. G. Yom-Tov, I. Nathan, O. Shpilberg, A. Polliack, and I. Levi Clomiphene as a novel modality for the treatment of acute myeloid leukemia: a pilot phase II study Leuk Res 36 2012 42 45
41. M. Poirot, P. De Medina, F. Delarue, J.J. Perie, A. Klaebe, and J.C. Faye Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS) Bioorg Med Chem 8 2000 2007 2016
42. L. Reyno, L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, V. Gorbunova, A. Garin, and J. Jassem Phase III study of N N-diethyl-2-[4- (phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA 19 J Clin Oncol 22 2004 269 276
43. T. Deng, J.C. Liu, K.I. Pritchard, A. Eisen, and E. Zacksenhaus Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4- (phenylmethyl)phenoxy]ethanamine/tesmilifene Clin Cancer Res 15 2009 119 130
44. J. Guo, J. Zhou, X. Ying, Y. Men, R.J. Li, Y. Zhang, J. Du, W. Tian, H.J. Yao, and X.X. Wang Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells J Pharm Pharm Sci 13 2010 136 151